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Abstract
Objective: The objective of this study was to assess the potential health and budgetary impacts of 
implementing a pharmacist-involved team-based hypertension management model in the United 
States.
Research Design: In 2017, we evaluated a pharmacist-involved team-based care intervention 
among 3 targeted groups using a microsimulation model designed to estimate cardiovascular event 
incidence and associated health care spending in a cross-section of individuals representative of 
the US population: implementing it among patients with: (1) newly diagnosed hypertension; (2) 
persistently (≥ 1 year) uncontrolled blood pressure (BP); or (3) treated, yet persistently 
uncontrolled BP—and report outcomes over 5 and 20 years. We describe the spending thresholds 
for each intervention strategy to achieve budget neutrality in 5 years from a payer’s perspective.
Results: Offering this intervention could prevent 22.9–36.8 million person-years of uncontrolled 
BP and 77,200–230,900 heart attacks and strokes in 5 years (83.8–174.8 million and 393,200–
922,900 in 20 years, respectively). Health and economic benefits strongly favored groups 2 and 3. 
Assuming an intervention cost of $525 per enrollee, the intervention generates 5-year budgetary 
cost-savings only for Medicare among groups 2 and 3. To achieve budget neutrality in 5 years 
across all groups, intervention costs per person need to be around $35 for Medicaid, $180 for 
private insurance, and $335 for Medicare enrollees.
Conclusions: Adopting a pharmacist-involved team-based hypertension model could 
substantially improve BP control and cardiovascular outcomes in the United States. Net cost-
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savings among groups 2 and 3 make a compelling case for Medicare, but favorable economics 
may also be possible for private insurers, particularly if innovations could moderately lower the 
cost of delivering an effective intervention.
Keywords
patient care team; hypertension; pharmacist; cost and cost analysis; economics; blood pressure; 
cardiovascular; disease; medicare; medicaid
The association between increased blood pressure (BP) and cardiovascular disease (CVD) 
risk has been well established, with increases in systolic blood pressure (SBP) being the 
greatest predictor of elevated risk.1–3 Hypertension affects ~29% of US adults, and despite a 
substantial number of pharmacologic options to lower BP and potentially reverse risk for 
CVD, only about half of US adults with hypertension have their BP controlled.4 
Furthermore, around 90% of the 40.2 million US adults with uncontrolled BP report having 
a usual source of health care.5,6 Team-based care interventions, which incorporate a 
multidisciplinary team of health care professionals to deliver more personalized patient-
centered care, have been found to be an effective approach to improving BP control.7,8 In 
particular, recent evidence indicates that involving pharmacists on the care team can 
significantly improve control.7,9,10
A recent study by Dehmer et al8 estimated that nationwide adoption of a program involving 
referral of patients with treated but persistently uncontrolled BP to adjunct care by a team 
that included a pharmacist or nurse could over 10 years: improve the BP control rate by 10 
percentage points, prevent over 600,000 CVD events, reduce associated health care costs 
borne by payers, and in some cases generate net budgetary savings, specifically for 
Medicare. This study builds on this previous work in 4 important ways. First, it examines the 
impact of a team-based hypertension management intervention involving a pharmacist, 
which is an evidence-based but underutilized model of team-based care.11 Second, the 
intervention is targeted among 3 different patients groups commonly encountered in clinical 
practice to assess for differences in expected health outcomes and costs. Third, compared 
with the previous study which only reported 10-year impacts among the overall target 
population, this analysis reports differential impacts across age-stratified and race-stratified 
subgroups over 5 years in the primary analysis—a shorter timeframe that is often of interest 
to payers—as well as over 20 years in the supplemental analysis to better assess how upfront 
costs are matched by downstream benefits. Finally, a break-even analysis was conducted to 
determine how varying select key parameters would affect costs borne by the various payers, 
and whether or when budget neutrality might occur from a specific payer’s perspective.
METHODS
Analyses were conducted in 2017 using the HealthPartners Institute ModelHealth: 
Cardiovascular disease (ModelHealth: CVD) microsimulation model. Methods to estimate 
risk of disease outcomes and costs in ModelHealth: CVD were consistent with those used by 
Dehmer et al.8 Briefly (see Methods, Supplemental Digital Content 1, http://
links.lww.com/MLR/B874), the model iterates through annual cycles simulating the lifespan 
and natural history of CVD among a dynamic cohort of 100,000 individuals representative 
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of the United States. Hypothetical individuals enter the analytic frame at age 35 years and 
exit the model either by reaching age 100 years or through a CVD-related or non–CVD-
related death.
Population-based survey data were used to develop the initial demographic characteristics 
(American Community Survey), employment-related characteristics (Current Population 
Surveys), and CVD risk profile (National Health and Nutrition Examination Survey and 
National Health Interview Survey) of the baseline population (Table 1).8 Disease outcomes 
were predicted by 1-year risk equations estimated specifically for the model from 
Framingham Heart Study data. Event risk was based on age, sex, body mass index, SBP, 
blood cholesterol levels, smoking status, and history of CVD. Incident and ongoing disease 
costs from a previous event were differentiated and estimated from actual expenditures by 
using Medical Expenditure Panel Survey data (see Table 1, Supplemental Digital Content 1, 
http://links.lww.com/MLR/B8748). Initial insurance status was derived from Current 
Population Survey data and year-to-year transitions were determined from Survey of Income 
and Program Participation data. Primary health outcomes reported include the number of 
person-years with uncontrolled BP (defined as SBP ≥ 140 mm Hg) and the number of 
incident myocardial infarctions, strokes, and total CVD-related events and deaths.13 
Economic outcomes reported include intervention costs, CVD-related costs, and net 
budgetary costs borne by payers, such as Medicaid, Medicare, and private insurers. All 
monetary measures are presented in 2012 US dollars.
A hypothetical intervention was designed to involve referral to a team-based hypertension 
management program involving a pharmacist, where the pharmacist worked with the patient 
to improve their medication adherence and could adjust the patient’s medication regimen to 
improve their BP. An updated literature search was conducted to identify randomized-
controlled trials (RCTs) examining team-based hypertensive care interventions with 
pharmacists published through 2016. Further details of the search and on the methods used 
to derive the effectiveness of the interventions are included in the Supplemental Methods 
(see Supplemental Digital Content 1, http://links.lww.com/MLR/B874).8 From the 20 RCTs 
identified from our search,14–33 we estimated and assumed the average benefit of 
participating in the team-based intervention involving pharmacists was an 8.5 mm Hg 
reduction in SBP. As many adults with hypertension have other risk factors for CVD or 
chronic conditions (eg, dyslipidemia)—and hypertension is unlikely to be managed in 
isolation—we assumed our intervention led to an average 8.1 mg/dL reduction in low-
density lipoprotein cholesterol and had no effect on high-density lipoprotein cholesterol 
among patients taking medications for lipid management based on studies of similar 
interventions that measured these outcomes (see Methods, Supplemental Digital Content 1, 
http://links.lww.com/MLR/B874).22,26,34–36
The intervention was targeted and evaluated among 3 separate groups of adults aged 35 
years or older: group 1, all newly diagnosed hypertensive patients; group 2, patients, 
regardless of treatment status, with persistent, uncontrolled hypertension, defined as SBP > 
140 mm Hg for ≥ 1 year; and group 3, patients included in group 2 who had adhered to 
treatment (ie, taking medication) for > 1 year, but remained uncontrolled (ie, the approach 
used in Dehmer et al’s8 previous publication). As in the previous study, we assumed that 
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90% of persons offered the program participated, the persisting treatment effect in each 
subsequent year would be 80% of the previous year, and patients in groups 2 and 3 were 
eligible to re-enroll in the program every 5 years if their BP remained or became 
uncontrolled.8 Furthermore, we assumed the intervention involved an average of 1-hour long 
intake visit, three 15-minute in-person visits, and eight 15-minute phone visits in 1 year, 
with an average annual cost of $525 per person enrolled.8 The costs incurred were in 
addition to the usual care costs of managing hypertension, which was assumed to be the 
same regardless of the addition of the intervention.
For each targeted group, the model generated outcomes in 2 otherwise parallel simulation 
arms over 5 years and, for the supplemental analysis, over 20 years—1 arm received the 
intervention and the other arm did not. Health impacts and costs reflect the difference 
between these 2 arms and are representative of and scaled to the US population aged 35 
years or older. Furthermore, the intervention cost, intervention effectiveness, or disease costs 
were varied to estimate threshold values at which each of the payers could break even in 
terms of achieving budget neutrality in 5 years when implementing the intervention among 
each group.
RESULTS
Our initial simulated cohort consisted of 162.8 million adults aged 35 years or older (Table 
1). Among the baseline population, 20.0% had uncontrolled BP, with 44.5% of those 
receiving pharmacologic treatment. At the time of enrollment, characteristics of the program 
enrollees differed by implementation strategy. Persons enrolled in group 1 (N = 25.8 
million) were younger, less obese, had a higher proportion of persons enrolled with private 
insurance, and had a lower mean SBP, a lower proportion of persons treated for elevated 
low-density lipoprotein cholesterol, and a lower proportion of persons diagnosed with CVD 
(Table 1). Persons enrolled in groups 2 (N = 33.2 million) and 3 (N = 30.2 million) were 
similar across demographics and health characteristics.
Five years after intervention implementation, we would expect to reduce uncontrolled BP by 
22.9, 36.8, and 32.8 million person-years when targeting groups 1–3, respectively (Table 2). 
The intervention had the largest effect on reducing myocardial infarctions (91,900), strokes 
(139,000), and CVD deaths (115,400) for group 2. The intervention had a slightly lower 
impact on these health outcomes for group 3 (3%–11% less compared with group 2), and 
considerably less impact (45%–75% less compared with group 2) for group 1. Patterns 
observed in the health impacts were similar across age and racial/ethnic groups for each of 
the targeted groups (Table 3). We estimated that the largest reductions in person-years with 
uncontrolled BP and CVD events would take place among Medicare beneficiaries in targeted 
groups 2 and 3, but not in group 1, for which the greatest reductions were among persons 
with private insurance.
Overall, the net cost per person enrolled (ie, total cost of the intervention minus costs averted 
by preventing events divided by the total population receiving the intervention) was 
considerably lower when implemented among groups 2 and 3 at $156 and $141 per person, 
respectively, compared with group 1, which was almost double at $322 per person (Table 2). 
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Similarly, the net cost per person achieving BP control was more favorable among persons 
in groups 2 and 3 ($246 and $223 vs. $690 in group 1). The disease costs averted over 5 
years fall short of the costs of delivering the intervention for all age and race-ethnic 
subgroups except among persons aged 75 years or older across all targeted groups (Table 4). 
Examining cost impacts disaggregated by payer indicates that disease costs averted outweigh 
the intervention costs over 5 years among Medicare beneficiaries only for groups 2 and 3 
(net savings/enrollee of $62 and $61, respectively). Whereas, the net cost of the intervention, 
when implemented among group 1, was estimated to be $190 per person enrolled. For the 
other major payers (ie, private insurers and Medicaid), the intervention would not yield cost-
savings for any of the targeted groups over 5 years. Net costs per person enrolled range from 
$291 to $346 for private insurers and were higher for Medicaid (range: $454–$493).
Table 5 presents results from the break-even analysis for each targeted group over 5 years. 
The most direct means to achieve budget neutrality would be to deliver the intervention at a 
lower cost per enrollee. For Medicare, intervening among persons with persistently 
uncontrolled BP (groups 2 and 3) would be cost-saving; however, when directed towards 
patients with newly diagnosed hypertension (group 1), the intervention cost would have to 
be below $335 per enrollee to be cost-saving; or, alternatively, the effectiveness of the 
intervention would need to be 65% higher or disease costs would need to be 60% higher. 
Private insurers could break-even in 5 years if the intervention could be delivered at or below 
$180, $220, or $230 per enrollee for each of the 3 targeted groups, respectively. For 
Medicaid, the intervention would have to be delivered at $35, $70, and $55 per enrollee, 
respectively. Similarly, the net balance in costs over 5 years could be affected by the 
magnitude in disease costs that could be averted. We found that disease treatment costs 
would need to greatly exceed the average to achieve cost neutrality for private insurers and 
Medicaid (range from +125% to +1505%). Achieving cost-savings for these payers through 
a more effective intervention would require average improvements in SBP > 20 mm Hg.
From the supplemental analysis, which assessed the effects of the intervention over 20 years, 
we would expect to reduce the number of person-years with uncontrolled BP by 83.8, 174.8, 
and 157.8 million person-years in the targeted groups 1–3, respectively (see Table, 
Supplemental Digital Content 2, http://links.lww.com/MLR/B875). Similar to our primary 
analyses, implementing the intervention among group 2 had the largest health and economic 
impact. Over 20 years, the disease costs averted outweigh the cost of the intervention for 
targeted groups 2 and 3 for Medicare and private insurers.
DISCUSSION
This analysis demonstrates that broad implementation of a team-based care intervention 
involving a pharmacist among patients with newly diagnosed hypertension or persistently 
uncontrolled BP could prevent at least 22.9 million person-years of uncontrolled BP, 40,600 
heart attacks, 36,600 strokes, and 63,400 CVD deaths over 5 years in the United States. 
Targeting the intervention among patients with persistently uncontrolled BP (groups 2 and 3) 
likely will generate greater health impacts compared with targeting newly diagnosed 
hypertensive patients (group 1), and should achieve cost-savings for Medicare within 5 years 
(~$0.9 billion). The greater impact (ie, prevented events and reduced health care spending) 
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of the intervention when implemented among groups 2 and 3 was driven largely by the 
baseline CVD risk of the targeted populations eligible for the intervention, as patients in 
groups 2 and 3 tended to be older and have higher baseline BPs compared with group 1. 
Enrollees with Medicare coverage had the lowest net intervention cost per enrollee across all 
targeted groups due to their higher age and BP at baseline that resulted in relatively more 
preventable events by way of intervention.
Achieving budget neutrality or cost-savings within 5 years is likely an important 
consideration for health plans considering widespread use of this intervention among its 
enrollees; however, these thresholds were not achieved across most of the payer types and 
among each targeted group. Finding a more effective intervention is an unlikely approach to 
achieve budget neutrality in 5 years across all payer types, as attaining a SBP reduction of > 
20 mm Hg is only supported by 2 of the studies used to inform the intervention effect size 
applied in this study (range across studies: 3.5–27.5 mm Hg).14–18,20,22–33 However, it does 
appear possible to deliver a similarly effective intervention at a lower cost than the $525 per 
enrollee assumed in this study. For example, an economic analysis by the Community 
Preventive Services Task Force found that based on evidence from 20 studies, the median 
team-based intervention cost was $284 per enrollee.37 If the intervention cost could be 
lowered to ≤ $180 through the use of existing or emerging technology (eg, electronic health 
records, web-based/smartphone communications, etc.),9 net savings could be attained within 
5 years for Medicare and private insurers across all targeted groups. For example, tailoring 
the duration of the intervention to each patient’s need to achieve BP control could 
substantially reduce the resources needed to deliver an effective intervention.38 Although 
this may be outside the time horizon important to most payers, sustaining the intervention 
over 20 years yields cost-savings for Medicare and private insurers among all targeted 
groups. The intervention would have to be offered at a considerably lower cost to achieve 
budget neutrality for Medicaid programs regardless of the group or timeframe used. 
However, the societal benefits of improving BP control among Medicaid enrollees, a 
younger population who typically has a greater health and economic burden of hypertension 
and other chronic diseases compared with similarly aged peers, may support the 
intervention’s use even if achieving budget neutrality is likely unattainable.39
High-performing multidisciplinary care teams are emerging as essential tools for more 
patient-centered, coordinated, and effective health care delivery systems.40 Integrating 
pharmacists on teams and allowing them to provide care to the full extent of their 
professional training, can help address shortages in primary care clinician and cardiologist 
availability while promoting safe medication use and optimizing therapeutic outcomes.
11,41–43
 As members on a multidisciplinary team, pharmacists can provide: comprehensive 
medication management (ie, initiating, modifying, synchronizing, and discontinuing 
medication to address identified problems), education on proper use of medication regimens, 
and additional opportunities for patient screening and assessment (ie, identifying barriers to 
adherence and measuring BP to ensure BP control goals are being achieved).
Although there is compelling evidence demonstrating that team-based care models with 
pharmacists are effective in improving BP control, variation exists in how these models are 
constructed and used.7,37 For example, in the 20 RCTs assessed for this study,14–33 
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pharmacist involvement in medication management differed, in that some pharmacists could 
act autonomously (ie, they could initiate, change, or discontinue medications independent of 
the primary care clinician); whereas, others could provide recommendations and/or make 
changes with the primary care clinician’s approval. In addition, how pharmacists were 
included on the team differed, as some were embedded directly on the team as an employee 
of a practice or health care system; whereas others were community pharmacists who 
participated in the team via other mechanisms. For example, community pharmacists can 
establish collaborative practice agreements with a practice or health care systems, which can 
support the delivery of collaborative care by identifying which functions are delegated to 
pharmacists, specifying how care will be coordinated, and establishing trust between 
pharmacists and primary care clinicians by following a mutually agreed upon, evidence-
based protocol.5,44 Although having heterogeneity in how teams are constructed and used 
may be appropriate to account for differences in the needs and preferences of the patient 
populations being managed, this heterogeneity could lead to variation in the outcomes 
assessed in this study. Hence, there is likely benefit for continued study on how to optimize 
use of team-based care models with pharmacists for hypertension management to achieve 
the greatest health and economic benefits across diverse patient populations.
Pharmacists can contribute considerably to value-based payment reform as they can help 
better align the services provided by the primary care team with specific pay-for-
performance metrics, such as those for clinical services or medication utilization.45 For 
instance, pharmacists have the opportunity to offer and extend their services with several 
improvement activities in Centers for Medicare and Medicaid Services merit-based incentive 
payment system. These include, but are not limited to, medication management practice 
improvements and implementation of chronic disease self-management support program.46 
Furthermore, in 2016, Centers for Medicare and Medicaid Services unveiled a new enhanced 
medication therapy management initiative to better integrate pharmacists in the Medicare 
Part D program in an effort to improve medication choices, adherence, and ultimately, health 
outcomes among seniors.47
Although this study builds on Dehmer and colleagues’ previous work by providing findings 
specific to the use of a team-based model of care involving pharmacists—a considerably 
underutilized evidence-based intervention11—it shares many of the same potential 
limitations as the earlier report.8 First, we are limited by our model assumptions related to 
the design, costs, and effects of the intervention, as well as, to the adherence to the 
intervention. As described above, components of a team-based care intervention (ie, team 
members, health care settings, eligible population, protocols, etc.) differed among the studies 
used to develop our effect size, and the average effect size used in our model may not be 
applicable for different populations or settings. Second, we required patients to meet specific 
conditions to be eligible for our targeted groups; however, these stipulations were not always 
prerequisites employed in the studies we derived the effects of our interventions from. Third, 
while findings for 5-and 20-year time horizons provide a better understanding how upfront 
costs are offset by downstream benefits, the latter may not be as meaningful to some payers 
because of high enrollee churn (eg, Medicaid) or shorter-term planning horizons (eg, private 
insurers). Fourth, the assumption of a 90% participation rate was chosen to reflect a 
potentially plausible “full uptake” of the intervention but may be “stretch” goal for many 
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settings. If the intervention had less reach but was delivered in a way that the group of 
patients selected to receive the intervention had a similar distribution of CVD risk and 
likelihood of benefitting from the intervention as those who received the intervention in our 
main analyses, then the overall results would simply scale down with no changes in findings 
for the net-cost-per-patient and break-even analyses. For example, if participation was 70% 
rather than the assumed 90%, the intervention costs and averted disease costs would be 
about 22% lower, but their relative scales and break-even points would remain unchanged. 
However, this assumption is not valid if the intervention was delivered among a group of 
patients whose overall characteristics differed from those of the originally selected patients 
(eg, if targeted to patients with higher baseline CVD risk). Finally, the current analysis does 
not apply the criteria outlined within the newly released 2017 American College of 
Cardiology and American Heart Association Hypertension Guideline,48 which lowered the 
recommended BP thresholds to initiate pharmacology therapy and to achieve BP control 
used in this study.13 Lowering these thresholds would increase the number of patients 
receiving the intervention in each targeted group and lead to additional events being 
prevented. However, it could produce a less advantageous net change in disease costs as the 
population newly eligible for the interventions would likely be at lower risk for having an 
event compared with those previously eligible.
This analysis shows that the adoption of a team-based hypertension management model of 
care involving pharmacists could greatly improve BP control rates and CVD outcomes in the 
United States across all 3 groups assessed. The greatest health and budgetary benefits were 
produced when the intervention was implemented among patients with persistently 
uncontrolled BP, leading to cost-savings for Medicare within 5 years. Private insurers could 
achieve budget neutrality by lowering intervention costs or implementing the intervention 
over a longer time horizon. Including pharmacists on care teams and allowing them to 
practice to the full extent of their professional training can support the medication 
management of hypertension, as well as other chronic conditions, leading to improved health 
for patients while remaining economically feasible.
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TABLE 2.
Health and Cost Impacts of Implementing the Team-based Care Hypertension Intervention Involving 
Pharmacists on a Simulated Sample Representative of the US Population Over 5 Years Compared With Usual 
Care, by Targeted Population Group
Target Group 1 (Newly 
Diagnosed Hypertension)
Target Group 2 
(Persistently Uncontrolled 
Blood Pressure)
Target Group 3 (Treated, 
But Persistently 
Uncontrolled Blood 
Pressure)
Person-years with uncontrolled BP (millions)* −22.9 −36.8 −32.8
Incident myocardial infarction (thousands) −40.6 −91.9 −87.8
Incident stroke (thousands) −36.6 −139.0 −134.5
Incident cardiovascular death (thousands) −63.4 −115.4 −107.9
Disease costs (billions USD) −5.3 −12.3 −11.6
Intervention costs (billions USD) 13.6 17.4 15.9
Net cost per person enrolled (USD) 322 156 141
Net cost per person achieving BP control (USD) 690 246 223
*Uncontrolled blood pressure was defined as systolic blood pressure ≥ 140 mm Hg. BP indicates blood pressure.
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TABLE 5.
Results of Break-even Analysis Demonstrating Threshold Values of Key Parameters to Achieve Budget 
Neutrality Within 5 Years Among the 3 Targeted Groups, by Payer Type
Break-even Thresholds to Achieve Budget Neutrality
Modeling Parameters by Payer
Target Group 1 (Newly 
Diagnosed Hypertension)
Target Group 2 (Persistently 
Uncontrolled Blood 
Pressure)
Target Group 3 (Treated, But 
Persistently Uncontrolled 
Blood Pressure)
Private Insurance
 Intervention cost per enrollee ($) 180 220 230
 Intervention effect on SBP (mm Hg) >20.0 >20.0 >20.0
 Change in disease costs (± %)* +195 +135 +125
Medicare
 Intervention cost per enrollee ($) 335 585 585
 Intervention effect on SBP (mm Hg) 14.0 7.5 8.0
 Change in disease costs (± %)* +60 −10 −10
Medicaid
 Intervention cost per enrollee ($) 35 70 55
 Intervention effect on SBP (mm Hg) >20.0 >20.0 >20.0
 Change in disease costs (± %)* +1505 +635 +645
*
These values represent the change in the cost to care for the events prevented that would be required to offset the costs of the intervention and 
achieve budget neutrality.
SBP indicates systolic blood pressure.
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